26 completed, 2 unknown, 2 withdrawn, 1 recruiting. 18 Phase 2, 9 Phase 3, 4 Phase 1, 2 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 13, Unknown 2, Withdrawn 2, Terminated 1 |
| Phase 3 | 9 | Completed 9 |
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Not applicable | 2 | Completed 2 |
| Phase 4 | 1 | Recruiting 1 |
Follow Maruho Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Topical BX005-A in Subjects With Moderate to Severe Atopic Dermatitis BX005-A, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Withdrawn | BiomX, Inc. | 2022-05-01 | 2025-08-03 | |
| An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis nemolizumab - Systemic Sclerosis | Phase 2 | Completed | Maruho Co., Ltd. | 6 | 2022-04-20 | 2026-02-13 |
| A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis pefcalcitol ointment, 0.005% - Psoriasis | Phase 2 | Withdrawn | Maruho Co., Ltd. | 2019-06-01 | 2023-04-18 | |
| Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis Omiganan, Ketoconazole, Placebo - Seborrheic Dermatitis | Phase 2 | Unknown | Maruho Co., Ltd. | 36 | 2018-10-22 | 2019-05-01 |
| Topical Ionic Contra-Viral Therapy in Actinic Keratosis ICVT Topical Gel, Furosemide Topical Gel, Digoxin Topical Gel - Actinic Keratosis | Phase 2 | Unknown | Maruho Co., Ltd. | 32 | 2018-10-22 | 2019-05-01 |
| Intradermal LPS and Antibiotics Erythromycin 4% topical gel formulation:, Clindamycin 1% lotion formulation:, Prednisolone tablet (0.5mg/kg; parallel comparison): - Inflammation; Skin | Not applicable | Completed | Centre for Human Drug Research, Netherlands | 32 | 2018-10-12 | 2021-08-03 |
| Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients Erythromycin 4% topical gel formulation, Clindamycin 1% topical lotion formulation, 70% topical ethanol solution - Acne Vulgaris | Phase 4 | Recruiting | Centre for Human Drug Research, Netherlands | 30 | 2018-03-20 | 2019-03-20 |
| A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts CLS006, CLS006 Vehicle - Cutaneous Common Warts | Phase 3 | Completed | Maruho Co., Ltd. | 491 | 2017-10-30 | 2023-09-14 |
| Wound Healing in Healthy Volunteers Observation of wound healing - Wound Healing | Not applicable | Completed | Centre for Human Drug Research, Netherlands | 18 | 2017-10-26 | 2021-08-03 |
| ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients CLS003, Vehicle - HPV-Induced Genital Lesions | Phase 2 | Terminated | Maruho Co., Ltd. | 28 | 2017-10-05 | 2019-03-20 |
| Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis Omiganan, Placebo - Atopic Dermatitis | Phase 2 | Completed | Maruho Co., Ltd. | 80 | 2017-03-08 | 2017-12-27 |
| Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers Omiganan, Imiquimod, Omiganan 1% and Imiquimod - Healthy | Phase 1 | Completed | Maruho Co., Ltd. | 16 | 2017-02-06 | 2017-05-22 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts CLS006 (Furosemide) Topical Gel, Vehicle Topical Gel - Cutaneous Common Warts | Phase 3 | Completed | Maruho Co., Ltd. | 484 | 2017-01-01 | 2023-09-14 |
| Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts Omiganan (CLS001) topical gel, Vehicle topical gel - Condylomata Acuminata (External) | Phase 2 | Completed | Maruho Co., Ltd. | 24 | 2016-07-01 | 2017-03-31 |
| Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle CLS001 (Omiganan), Vehicle - Rosacea | Phase 3 | Completed | Maruho Co., Ltd. | 463 | 2015-12-01 | 2022-08-02 |
| Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN Omiganan (CLS001) topical gel, Vehicle topical gel - Usual Type Vulval Intraepithelial Neoplasia (uVIN) | Phase 2 | Completed | Maruho Co., Ltd. | 12 | 2015-11-01 | 2017-08-03 |
| Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle CLS001 (Omiganan), Vehicle - Rosacea | Phase 3 | Completed | Maruho Co., Ltd. | 263 | 2015-10-01 | 2022-08-02 |
| A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris Omiganan (CLS001) Topical Gel, Vehicle Topical Gel - Acne Vulgaris | Phase 2 | Completed | Maruho Co., Ltd. | 320 | 2015-10-01 | 2017-03-27 |
| Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel Omiganan - Rosacea | Phase 3 | Completed | Maruho Co., Ltd. | 307 | 2015-10-01 | 2022-07-19 |
| Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis CLS001, Vehicle - Atopic Dermatitis | Phase 2 | Completed | Maruho Co., Ltd. | 37 | 2015-05-01 | 2016-07-28 |
Showing 20 of 32. Sign in to see all of them.
Rosacea (5) · Dermatitis, Atopic (4) · Acne Vulgaris (3) · Herpes Simplex (2) · Psoriasis (2) · Condylomata Acuminata (1) · Dermatitis (1) · Dermatitis, Seborrheic (1) · Herpes Zoster (1) · Keratosis, Actinic (1) · Scleroderma, Systemic (1)
Omiganan (10) · Gels (4) · ASP2151 (3) · Clindamycin (2) · Erythromycin (2) · Furosemide (2) · Cholecalciferol (1) · Clobetasol (1) · Digoxin (1) · Dosage Forms (1) · Imiquimod (1) · Ketoconazole (1) · Lipopolysaccharides (1) · Prednisolone (1) · Valacyclovir (1)
Netherlands (16) · United States (10) · United Kingdom (5) · France (4) · Germany (4) · Japan (4) · Australia (3) · Canada (3) · New Zealand (3) · Sweden (3) · Poland (2) · Austria (1) · Bulgaria (1) · Hungary (1) · Lithuania (1)
Robert Rissmann, PhD (3) · Ayumi Yoshizaki, MD, PhD (1) · D Thaci, Prof.Dr (1) · Maruho Co.,Ltd. Kyoto R&D Center (1) · Matthijs Moerland, PhD (1) · Robert Rissmann, PharmD, PhD (1) · Urania Rappo, MD (1)
PMID 31755993, PMID 30580460, PMID 32315497, PMID 36781451
2016 (2), 2014 (1), 2015 (1)